Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults
The Belgian Superior Health Council (SHC) preferentially recommended the 20-valent pneumococcal conjugate vaccine (PCV20) for adults aged ≥65 years, immunocompromised patients, and patients aged ≥50 years suffering from conditions that increase their risk for pneumococcal infections. The objective of this paper is to present the cost-utility of PCV20 compared to no vaccination and the alternative sequence of PCV15 followed by the 23-valent pneumococcal polysaccharide vaccine (PPV23) in this population. The analysis employed a static Markov model capturing lifetime risk of pneumococcal infectio... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Dataset |
Erscheinungsdatum: | 2023 |
Schlagwörter: | Medicine / Microbiology / Biotechnology / Sociology / Immunology / Cancer / Science Policy / Virology / Biological Sciences not elsewhere classified / Pneumococcal vaccination / PCV20 / cost-effectiveness / cost-utility / adults |
Sprache: | unknown |
Permalink: | https://search.fid-benelux.de/Record/base-27306132 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.6084/m9.figshare.24486529.v1 |